Thermo Fisher Scientific's consistent revenue streams and strong M&A track record position it well for growth. The company's valuation multiples are now reasonable, and it is expected to benefit from improved biotech funding and China's government stimulus by 2025, indicating a positive short-term impact on its stock price.